IDDI, whose expertise in the management and analysis of patient clinical data is recognized worldwide, is changing its shareholding to perpetuate its structure and continue its development in Europe and the United States. The Société Régionale d’Investissement de Wallonie (SRIW) thus takes a 20% stake in the company’s capital and supports the increase in management participation to 30%.
Created in 1991 by Marc Buyse, a world-renowned expert in the field of biostatistics, IDDI (International Drug Development Institute), has today become a key company in its field both in Europe and the United States. She has developed unique expertise in the optimization, conduct and analysis of clinical trials evaluating new drugs and in the statistical validation of new biomarkers. Its unique approach combines advanced biostatistical methods and innovative technological solutions in the collection and processing of clinical data. Based in Louvain-la-Neuve, the company has conquered the United States where most of the major players in the pharmaceutical and biotechnology sectors are located. Active in the USA for 20 years, IDDI has opened new offices in Raleigh (North Carolina) to offer even closer service to its American customers.
“The entry of SRIW into the shareholder base of the IDDI group strengthens the financial structure of our group,” confides Marc Buyse, who remains the majority shareholder and Chief Scientific Officer of the company. “The strengthening of executive participation in the shareholding reflects management’s desire for continuity and sustainability of IDDI.”